Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project

A. van Luijtelaar, B. M. Greenwood, H. U. Ahmed, A. B. Barqawi, E. Barret, J. G.R. Bomers, M. A. Brausi, P. L. Choyke, M. R. Cooperberg, S. Eggener, J. F. Feller, F. Frauscher, A. K. George, R. G. Hindley, S. F.M. Jenniskens, L. Klotz, G. Kovacs, U. Lindner, S. Loeb, D. J. MargolisL. S. Marks, S. May, T. D. Mcclure, R. Montironi, S. G. Nour, A. Oto, T. J. Polascik, A. R. Rastinehad, T. M. De Reyke, J. S. Reijnen, J. J.M.C.H. de la Rosette, J. P.M. Sedelaar, D. S. Sperling, Eric Walser, J. F. Ward, A. Villers, S. Ghai, J. J. Fütterer

Research output: Contribution to journalArticle

Abstract

Purpose: To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi consensus method. Methods: A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings. Results: Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa (csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation. Conclusion: Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer follow-up is mandatory before widespread clinical implementation is justified.

Original languageEnglish (US)
JournalWorld Journal of Urology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Laser Therapy
Prostatic Neoplasms
Neoplasm Grading
Magnetic Resonance Imaging
Therapeutics
Biopsy
Tumor Burden
Patient Selection
Clinical Trials
Recurrence

Keywords

  • Consensus
  • Delphi
  • Focal laser ablation
  • Laser focal therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

van Luijtelaar, A., Greenwood, B. M., Ahmed, H. U., Barqawi, A. B., Barret, E., Bomers, J. G. R., ... Fütterer, J. J. (Accepted/In press). Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World Journal of Urology. https://doi.org/10.1007/s00345-019-02636-7

Focal laser ablation as clinical treatment of prostate cancer : report from a Delphi consensus project. / van Luijtelaar, A.; Greenwood, B. M.; Ahmed, H. U.; Barqawi, A. B.; Barret, E.; Bomers, J. G.R.; Brausi, M. A.; Choyke, P. L.; Cooperberg, M. R.; Eggener, S.; Feller, J. F.; Frauscher, F.; George, A. K.; Hindley, R. G.; Jenniskens, S. F.M.; Klotz, L.; Kovacs, G.; Lindner, U.; Loeb, S.; Margolis, D. J.; Marks, L. S.; May, S.; Mcclure, T. D.; Montironi, R.; Nour, S. G.; Oto, A.; Polascik, T. J.; Rastinehad, A. R.; De Reyke, T. M.; Reijnen, J. S.; de la Rosette, J. J.M.C.H.; Sedelaar, J. P.M.; Sperling, D. S.; Walser, Eric; Ward, J. F.; Villers, A.; Ghai, S.; Fütterer, J. J.

In: World Journal of Urology, 01.01.2019.

Research output: Contribution to journalArticle

van Luijtelaar, A, Greenwood, BM, Ahmed, HU, Barqawi, AB, Barret, E, Bomers, JGR, Brausi, MA, Choyke, PL, Cooperberg, MR, Eggener, S, Feller, JF, Frauscher, F, George, AK, Hindley, RG, Jenniskens, SFM, Klotz, L, Kovacs, G, Lindner, U, Loeb, S, Margolis, DJ, Marks, LS, May, S, Mcclure, TD, Montironi, R, Nour, SG, Oto, A, Polascik, TJ, Rastinehad, AR, De Reyke, TM, Reijnen, JS, de la Rosette, JJMCH, Sedelaar, JPM, Sperling, DS, Walser, E, Ward, JF, Villers, A, Ghai, S & Fütterer, JJ 2019, 'Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project', World Journal of Urology. https://doi.org/10.1007/s00345-019-02636-7
van Luijtelaar, A. ; Greenwood, B. M. ; Ahmed, H. U. ; Barqawi, A. B. ; Barret, E. ; Bomers, J. G.R. ; Brausi, M. A. ; Choyke, P. L. ; Cooperberg, M. R. ; Eggener, S. ; Feller, J. F. ; Frauscher, F. ; George, A. K. ; Hindley, R. G. ; Jenniskens, S. F.M. ; Klotz, L. ; Kovacs, G. ; Lindner, U. ; Loeb, S. ; Margolis, D. J. ; Marks, L. S. ; May, S. ; Mcclure, T. D. ; Montironi, R. ; Nour, S. G. ; Oto, A. ; Polascik, T. J. ; Rastinehad, A. R. ; De Reyke, T. M. ; Reijnen, J. S. ; de la Rosette, J. J.M.C.H. ; Sedelaar, J. P.M. ; Sperling, D. S. ; Walser, Eric ; Ward, J. F. ; Villers, A. ; Ghai, S. ; Fütterer, J. J. / Focal laser ablation as clinical treatment of prostate cancer : report from a Delphi consensus project. In: World Journal of Urology. 2019.
@article{033ecc0b062f496da2e683d4d2407dcd,
title = "Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project",
abstract = "Purpose: To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi consensus method. Methods: A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings. Results: Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa (csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation. Conclusion: Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer follow-up is mandatory before widespread clinical implementation is justified.",
keywords = "Consensus, Delphi, Focal laser ablation, Laser focal therapy, Prostate cancer",
author = "{van Luijtelaar}, A. and Greenwood, {B. M.} and Ahmed, {H. U.} and Barqawi, {A. B.} and E. Barret and Bomers, {J. G.R.} and Brausi, {M. A.} and Choyke, {P. L.} and Cooperberg, {M. R.} and S. Eggener and Feller, {J. F.} and F. Frauscher and George, {A. K.} and Hindley, {R. G.} and Jenniskens, {S. F.M.} and L. Klotz and G. Kovacs and U. Lindner and S. Loeb and Margolis, {D. J.} and Marks, {L. S.} and S. May and Mcclure, {T. D.} and R. Montironi and Nour, {S. G.} and A. Oto and Polascik, {T. J.} and Rastinehad, {A. R.} and {De Reyke}, {T. M.} and Reijnen, {J. S.} and {de la Rosette}, {J. J.M.C.H.} and Sedelaar, {J. P.M.} and Sperling, {D. S.} and Eric Walser and Ward, {J. F.} and A. Villers and S. Ghai and F{\"u}tterer, {J. J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00345-019-02636-7",
language = "English (US)",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Focal laser ablation as clinical treatment of prostate cancer

T2 - report from a Delphi consensus project

AU - van Luijtelaar, A.

AU - Greenwood, B. M.

AU - Ahmed, H. U.

AU - Barqawi, A. B.

AU - Barret, E.

AU - Bomers, J. G.R.

AU - Brausi, M. A.

AU - Choyke, P. L.

AU - Cooperberg, M. R.

AU - Eggener, S.

AU - Feller, J. F.

AU - Frauscher, F.

AU - George, A. K.

AU - Hindley, R. G.

AU - Jenniskens, S. F.M.

AU - Klotz, L.

AU - Kovacs, G.

AU - Lindner, U.

AU - Loeb, S.

AU - Margolis, D. J.

AU - Marks, L. S.

AU - May, S.

AU - Mcclure, T. D.

AU - Montironi, R.

AU - Nour, S. G.

AU - Oto, A.

AU - Polascik, T. J.

AU - Rastinehad, A. R.

AU - De Reyke, T. M.

AU - Reijnen, J. S.

AU - de la Rosette, J. J.M.C.H.

AU - Sedelaar, J. P.M.

AU - Sperling, D. S.

AU - Walser, Eric

AU - Ward, J. F.

AU - Villers, A.

AU - Ghai, S.

AU - Fütterer, J. J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi consensus method. Methods: A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings. Results: Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa (csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation. Conclusion: Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer follow-up is mandatory before widespread clinical implementation is justified.

AB - Purpose: To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi consensus method. Methods: A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings. Results: Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa (csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation. Conclusion: Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer follow-up is mandatory before widespread clinical implementation is justified.

KW - Consensus

KW - Delphi

KW - Focal laser ablation

KW - Laser focal therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85060556628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060556628&partnerID=8YFLogxK

U2 - 10.1007/s00345-019-02636-7

DO - 10.1007/s00345-019-02636-7

M3 - Article

AN - SCOPUS:85060556628

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -